Updated: Viridian reveals first Phase 3 eye disease data in bid to compete with Tepezza

Max Gelman

Senior Editor

Viridian Therapeutics on Tuesday reported topline Phase 3 data for its rare autoimmune disease drug veligrotug as it aims to compete with Amgen and Horizon …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Viridian reveals first Phase 3 eye disease data in bid to compete with Tepezza

Max Gelman

Senior Editor

Sign up to read this article for free.

Merck's Eliav Barr on subcutaneous Keytruda, Summit and deal shopping

In surprise, study suggests Covid mRNA vaccines may boost cancer immunotherapy efficacy

BioNTech rolls out Phase 2 lung cancer data as VEGF bispecifics take center stage

Roche outlines commercial manufacturing strategy for GLP-1/GIP assets

Boehringer plans NDA filing for pulmonary fibrosis drug following Phase 3 data

Breaking down silos with a new quantitative approach to drug development

Up­dat­ed: Virid­i­an re­veals first Phase 3 eye dis­ease da­ta in bid to com­pete with Te­pez­za

Max Gelman

Senior Editor

Sign up to read this article for free.

Mer­ck­'s Eli­av Barr on sub­cu­ta­neous Keytru­da, Sum­mit and deal shop­ping

In sur­prise, study sug­gests Covid mR­NA vac­cines may boost can­cer im­munother­a­py ef­fi­ca­cy

BioN­Tech rolls out Phase 2 lung can­cer da­ta as VEGF bis­pecifics take cen­ter stage

Roche out­lines com­mer­cial man­u­fac­tur­ing strat­e­gy for GLP-1/GIP as­sets

Boehringer plans NDA fil­ing for pul­monary fi­bro­sis drug fol­low­ing Phase 3 da­ta

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

Updated: Viridian reveals first Phase 3 eye disease data in bid to compete with Tepezza

Merck's Eliav Barr on subcutaneous Keytruda, Summit and deal shopping

In surprise, study suggests Covid mRNA vaccines may boost cancer immunotherapy efficacy

BioNTech rolls out Phase 2 lung cancer data as VEGF bispecifics take center stage

Roche outlines commercial manufacturing strategy for GLP-1/GIP assets

Boehringer plans NDA filing for pulmonary fibrosis drug following Phase 3 data

Breaking down silos with a new quantitative approach to drug development